Related Experiment Videos

Antisense phosphorothioate oligonucleotides targeted to the human chemokine receptor CXCR4

A Kusunoki1, N Miyano-Kurosaki, T Kimura

  • 1Department of Industrial Chemistry, Chiba Institute of Technology, Narashino, Japan.

Insights

Antisense oligodeoxyribonucleotides targeting the CXCR4 gene effectively reduced its expression in Human Immunodeficiency Virus type 1 (HIV-1) infected cells. Delivery using RNP enhanced inhibition of viral products, suggesting a potential therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Virology
  • Immunology

Background:

  • CXC chemokine receptor CXCR4 is a critical co-receptor for Human Immunodeficiency Virus type 1 (HIV-1) entry.
  • Syncytia-inducing T-tropic (X4) HIV-1 isolates heavily rely on CXCR4 for cell fusion and infection.

Purpose of the Study:

  • To investigate the therapeutic potential of inhibiting CXCR4 gene expression using antisense oligodeoxyribonucleotides (anti-S-ODNs).
  • To evaluate the efficacy of anti-S-ODNs in X4 HIV-1 infected cells.

Main Methods:

  • Synthesis of antisense phosphorothioate oligodeoxyribonucleotides (anti-S-ODNs) targeting human CXCR4 mRNA.
  • Treatment of HeLa-CD4 cells infected with X4 HIV-1 using naked anti-S-ODNs.
  • Assessment of CXCR4 surface receptor levels via flow cytometry.
  • Evaluation of anti-S-ODN delivery enhancement using nucleosomal histone proteins (RNP).

Main Results:

  • Naked anti-S-ODNs reduced surface CXCR4 levels by up to 50% in a sequence-specific manner.
  • Anti-S-ODNs encapsulated with RNP demonstrated superior inhibition of p24 viral products compared to naked anti-S-ODNs.

Conclusions:

  • Antisense oligodeoxyribonucleotides are effective in inhibiting CXCR4 gene expression in X4 HIV-1 infected cells.
  • RNP-mediated delivery of anti-S-ODNs enhances therapeutic efficacy against HIV-1, offering a promising avenue for treatment.

Related Concept Videos